Santaris Pharma A/S - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Santaris Pharma A/S - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Santaris Pharma A/S - Product Pipeline Review - 2014', provides an overview of the Santaris Pharma A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Santaris Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Santaris Pharma A/S including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Santaris Pharma A/S's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Santaris Pharma A/S's pipeline products

Reasons to buy

- Evaluate Santaris Pharma A/S's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Santaris Pharma A/S in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Santaris Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Santaris Pharma A/S and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Santaris Pharma A/S
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Santaris Pharma A/S and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Santaris Pharma A/S Snapshot 5
Santaris Pharma A/S Overview 5
Key Information 5
Key Facts 5
Santaris Pharma A/S - Research and Development Overview 6
Key Therapeutic Areas 6
Santaris Pharma A/S - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Santaris Pharma A/S - Pipeline Products Glance 14
Santaris Pharma A/S - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Santaris Pharma A/S - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Santaris Pharma A/S - Drug Profiles 16
miravirsen 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
SPC-2968 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EZN-3889 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
EZN-3892 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
EZN-3920 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
SPC-4955 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
SPC-5001 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Santaris Pharma A/S - Pipeline Analysis 27
Santaris Pharma A/S - Pipeline Products by Target 27
Santaris Pharma A/S - Pipeline Products by Route of Administration 28
Santaris Pharma A/S - Pipeline Products by Molecule Type 29
Santaris Pharma A/S - Pipeline Products by Mechanism of Action 30
Santaris Pharma A/S - Recent Pipeline Updates 31
Santaris Pharma A/S - Dormant Projects 35
Santaris Pharma A/S - Discontinued Pipeline Products 36
Discontinued Pipeline Product Profiles 36
SPC-3042 36
Santaris Pharma A/S - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Santaris Pharma A/S, Key Information 5
Santaris Pharma A/S, Key Facts 5
Santaris Pharma A/S - Pipeline by Indication, 2014 7
Santaris Pharma A/S - Pipeline by Stage of Development, 2014 8
Santaris Pharma A/S - Monotherapy Products in Pipeline, 2014 9
Santaris Pharma A/S - Partnered Products in Pipeline, 2014 10
Santaris Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2014 11
Santaris Pharma A/S - Out-Licensed Products in Pipeline, 2014 12
Santaris Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Santaris Pharma A/S - Phase II, 2014 14
Santaris Pharma A/S - Preclinical, 2014 15
Santaris Pharma A/S - Pipeline by Target, 2014 27
Santaris Pharma A/S - Pipeline by Route of Administration, 2014 28
Santaris Pharma A/S - Pipeline by Molecule Type, 2014 29
Santaris Pharma A/S - Pipeline Products by Mechanism of Action, 2014 30
Santaris Pharma A/S - Recent Pipeline Updates, 2014 31
Santaris Pharma A/S - Dormant Developmental Projects,2014 35
Santaris Pharma A/S - Discontinued Pipeline Products, 2014 36
Santaris Pharma A/S, Other Locations 37